Taiwan’s Chang Gung Memorial Hospital selects RayStation for proton therapy
Chang Gung Memorial Hospital, a leading teaching hospital in Kaohsiung, Taiwan, has chosen RayStation as the treatment planning system for use with its new Sumitomo proton therapy system.
Established in 1976, the hospital has expanded rapidly and is now one of Taiwan’s foremost centers for treatment and research. The Proton and Radiation Therapy Center of Chang Gung Memorial Hospital was the first proton center in Taiwan, and the center provides advanced radiation therapy services to patients from Taiwan and internationally. Annually, it treats around 3,000 patients with photon radiation and 1,500 patients with protons.
The RayStation order, which was placed via Sumitomo Heavy Industries, comprises software, computer hardware, beam commissioning, user training and clinical licenses. Delivery is scheduled for August 2017, and commissioning will also take place during the year. The hospital expects to begin treating patients using the system in early 2018.
Kazuto Kaneshige, Senior Vice President, Sumitomo Heavy Industries, Ltd., says: “Sumitomo is very happy to supply RayStation to Chang Gung Memorial Hospital. RayStation will accommodate the hospital’s requirements and make it possible to fully exploit the capabilities of our proton therapy system.”
Johan Löf, CEO of RaySearch, says: “I am delighted to be able to support the proton planning needs of Chang Gung Memorial Hospital, which is a pioneer of cutting-edge techniques in Taiwan. Asia is a technologically advanced market and an important focus for RaySearch. We have a strong presence in the region, supporting a variety of different treatment machines, and we will continue to extend our partnerships with leading cancer centers.”
About Chang Gung Memorial Hospital
Chang Gung Memorial Hospital offers the largest and most comprehensive health care services in Taiwan, comprising a network of 7 hospital branches located in Linkou, Taipei, Taoyuan, Keelung, Yunlin, Chiayi, and Kaohsiung. The hospital network has a total of 10,050 beds. Each year, it has around 2.4 million inpatients and receives an average of 8.2 million outpatient visits. It is estimated that one-third of Taiwan’s population has sought treatment at Chang Gung.
About Sumitomo Heavy Industries (SHI)
SHI has been engaged in research and development for medical use of accelerators, such as cyclotrons, for over 40 years. In 1997, SHI delivered the first proton therapy system to National Cancer Center Hospital East in Japan, which was the first hospital-based proton therapy facility in Japan and the second in the world. Since then, SHI proton therapy systems have been delivered (or are planned to be delivered) to facilities in Japan, Taiwan and Korea. SHI contributes towards the wide use of proton therapy for cancer treatment around the world in collaboration with customers.
About RayStation
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®*, which comprises a new product area for RaySearch, and which will be launched in 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm, and the share has been listed on NASDAQ Stockholm since November 2003.
* Subject to regulatory clearance in some markets
More information about RaySearch is available at www.raysearchlabs.com
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
johan.lof@raysearchlabs.com
